Article Text

PDF
FRI0359 Intravenous cyclophosphamide combined therapy in severe lupus nephritis: Immediate and long-term results
  1. P. Vachvanichsanong1,
  2. P. Dissaneewate1,
  3. E. McNeil2
  1. 1Pediatrics
  2. 2Epidemiology Unit, Prince of Songkla University, Hat Yai, Thailand

Abstract

Background Intravenous cyclophosphamide (IVCY) has been used to treat severe lupus nephritis (LN) for many years. Because of the wide variety of manifestations of the condition and the long-term nature of the disease, outcomes vary widely.

Objectives To evaluate and compare the immediate and long-term results of IVCY in pediatric onset severe LN and between patients with normal and abnormal renal function.

Patients and Methods The records of patients aged <18 years who attended the Department of Pediatrics, Prince of Songkla University, diagnosed with severe LN, and who were given a 36-month IVCY course, were reviewed.

Results 108 patients were studied with a mean age of 12.6±2.7 years and mean follow up time of 5.7±4.3 years. 48 patients completed the 36-month IVCY course, 29 did not complete the course, and 31 were ongoing at the time of analysis.

There were 36 patients with abnormal renal function at the start of therapy and 72 with normal renal function. Abnormal renal function patients had a higher mortality rate than normal renal function patients (13/36 vs 10/72, p-value<0.001). Both groups responded well initially to treatment; proteinuria reduced to normal levels after 1 and 2 courses in the normal and abnormal renal function groups, respectively, while creatinine clearance returned to normal levels after 8 courses in patients with abnormal renal function.

Conclusions Three years of IVCY treatment reduced proteinuria in both normal and abnormal renal function patients; however the mortality rate was higher in patients with abnormal renal function.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.